The Yellow Card Scheme is run by the Medicines and Healthcare products Regulatory Agency (MHRA). The Scheme is used to collect information from Healthcare Professionals and patients on suspected Adverse Drug Reactions (ADRs). It is vital in helping the MHRA monitor the safety of the medicines and vaccines that are on the market.

Both Healthcare Professionals and patients can submit information through the Yellow Card website.

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Chugai or Roche Products Ltd using the details below.


Report an Adverse Reaction to Chugai Pharma UK Ltd
(for Granocyte, Aloxi and Akynzeo)
Telephone: +44 (0) 20 8987 5600
Email: [email protected]

Report an Adverse Reaction to Roche Products Ltd
(for Hemlibra and RoActemra)
Email: [email protected]

Adverse events for Hemlibra and RoActemra should be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing Roche. As Hemlibra and RoActemra are biological medicines, healthcare professionals should report adverse reactions by brand name and batch number.

For information about data processing within the scope of Pharmacovigilance, please refer to our Pharmacovigilance Privacy Notice.